EUS-guided Response Assessment to NSBB
Condition(s) studied
Investigational drug(s) / intervention(s)
endoscopic ultrasound-guided portal pressure measurement: The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
Study summary
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.
Eligibility
Primary outcome measure(s)
- EUS-guided response assessment to NSBB in the treatment of CSPH. — Three months
To assess if a positive response to non-selective beta-blockers (NSBB) treatment, as determined by a reduction of 10% or more in the hepatic venous pressure gradient (HVPG) and/or a decrease to values less than 12 mmHg, can be similarly observed using endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital Leuven | Leuven | Vlaams-Brabant | Recruiting |
More Universitaire Ziekenhuizen KU Leuven trials in Belgium
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06513195 on ClinicalTrials.gov ↗ ← All trials in Belgium